

**HOUSE . . . . . No. 01480**

---

---

The Commonwealth of Massachusetts

\_\_\_\_\_  
PRESENTED BY:

*Gloria L. Fox*

\_\_\_\_\_

*To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:*

The undersigned legislators and/or citizens respectfully petition for the passage of the accompanying bill:

An Act promoting research and protecting public safety and environment.

\_\_\_\_\_  
PETITION OF:

NAME:	DISTRICT/ADDRESS:
<i>Gloria L. Fox</i>	<i>7th Suffolk</i>
<i>Sonia Chang-Diaz</i>	<i>Second Suffolk</i>
<i>Benjamin Swan</i>	<i>11th Hampden</i>

# HOUSE . . . . . No. 01480

By Ms. Gloria L. Fox of Boston, petition (accompanied by bill, House, No. 01480) of Gloria L. Fox and others establishing a high containment biological research laboratory health and safety program by the Department of Public Health. Joint Committee on Public Health.

[SIMILAR MATTER FILED IN PREVIOUS SESSION  
SEE  
□ HOUSE  
□ , NO. 2051 OF 2009-2010.]

## The Commonwealth of Massachusetts

\_\_\_\_\_  
**In the Year Two Thousand Eleven**  
\_\_\_\_\_

An Act promoting research and protecting public safety and environment.

*Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:*

1 SECTION 1. Chapter 17 of the General Laws, as appearing in the 2004 official edition is hereby  
2 amended by inserting after section 17 the following:-

3 Section 18. Biological Agents Registry Program

4 Definitions. As used in this section the following words shall have the following meanings:

5 “Biological agent,” any microorganism (including bacteria, virus, fungus, and protozoa), or  
6 infectious substance, or any naturally occurring, bioengineered, or synthesized component of any  
7 such microorganism or infectious substance, capable of causing: death, disease, or other  
8 biological malfunction in a human, an animal, a plant, or another living organism; deterioration

9 of food, water, equipment, supplies, or material of any kind; or deleterious alteration of the  
10 environment.

11 “Department,” the Department of Public Health.

12 “Person,” any state, public, or private corporation or authority, any individual, trust, firm, joint  
13 stock company, partnership, association, or other entity, or any group thereof, and any officer,  
14 employee, or agent of such person, any group of persons, and any agency or political subdivision  
15 of the Commonwealth or of the federal government.

16 “Program,” the Biological Agents Registry Program.

17 “Select Agents and Toxins” a biological agent or toxin as defined in Title 42, Part 73 of the Code  
18 of Federal Regulations, Title 9, Part 121 of the Code of Federal Regulations, or Title 7, Part 331  
19 of the Code of Federal Regulations.

20 “Toxin,” any toxic material or product of plants, animals, microorganisms (including bacteria,  
21 virus, fungus, rickettsiae, or protozoa), or infectious substance, or a recombinant or synthesized  
22 molecule, whatever their origin and method of production, and includes: any poisonous  
23 substance or biological product that may be engineered as a result of biotechnology produced by  
24 a living organism; or any poisonous isomer or biological product, homolog, or derivative of such  
25 a substance.

26 There is established in the department a Biological Agents Registry Program.

27 The Biological Agents Registry shall:

28

29 Identify the select agents and toxins, and other biological agents and toxins, as determined by the  
30 department, possessed and maintained by any person in the Commonwealth; and

31

32 Contain other information as required by regulations of the department.

33 The department shall adopt regulations for the implementation of the program that:

34

35 Determine and list the biological agents and toxins required to be reported under this section,  
36 which shall include:

37 All select agents and toxins, provided that the department may exempt select agents and toxins  
38 that Title 42, Part 72 or 73 of the Code of Federal Regulations, Title 9, Part 121 of the Code of  
39 Federal Regulation, or Title 7, Part 331 of the Code of Federal Regulations exempt from their  
40 provisions; and

41 Other biological agents and toxins as determined by the department.

42

43 Designate the persons required to make reports and the specific information required to be  
44 reported;

45

46 Designate time limits for reporting, the form of reports, and the persons to whom reports are to  
47 be submitted;

48

49 Require local boards of health to be informed of the location and nature of the biological agents  
50 and toxins in the registry that are located within the local jurisdiction;

51 Provide for the release of information in the Biological Agents Registry to:

52 Municipal, state and federal law enforcement agencies and the Centers for Disease Control and  
53 Prevention pursuant to a communicable disease or laboratory-acquired infection investigation  
54 commenced or conducted by the department or municipal, state, or federal law enforcement  
55 agency having investigatory authority, or in connection with any investigation involving a  
56 release, spread, theft, illicit sale, or loss of biological agents;

57 The Massachusetts emergency management agency and the Massachusetts department of the  
58 environmental protection for the purposes of planning for the protection of the public in relation  
59 to the release of a biological agent and the prevention of a release of a biological agent; and

60 The Massachusetts emergency medical services system for the purposes of providing certain  
61 specified information to:

62 (A) A police officer or firefighter responding to an emergency; and

63 (B) An emergency medical services provider performing emergency services responding to a fire  
64 or other emergency, or dispatched on a call for emergency services;

65 Establish a process for persons that possess and maintain select agents and toxins and other  
66 biological agents and toxins to alert appropriate authorities of unauthorized possession or  
67 attempted possession of such biological agents or toxins.

68 A person that possesses and maintains biological agents and toxins shall report to the department  
69 the information required by the department for inclusion in the Biological Agents Registry unless  
70 the department determines that the select agents and toxins, certified laboratory, or facility is  
71 exempt from the requirements for the interstate shipment of etiologic agents under Title 42, Part  
72 72.6(h) or Part 72, Appendix A of the Code of Federal Regulations.

73 Information prepared for or maintained in the Biological Agents Registry shall be subject to  
74 chapter 66 of the General Laws, provided that information released from the Registry is not  
75 consequently a public record and a person to whom information has been released from the  
76 Registry may not release the information unless such release is approved by the department.

77 A person who violates a provision of this section is guilty of a misdemeanor and on conviction is  
78 subject to a fine not exceeding \$1000 for the first offense and not exceeding \$5000 for each  
79 subsequent conviction for a violation of the same provision. Each day a violation is continued  
80 after the first conviction is a subsequent offense.

#### 81 Section 19. High Containment Biological Research Laboratory Health and Safety Program

82 Definitions. As used in this section the following words shall have the following meanings:

83 “Biological agent,” any microorganism (including bacteria, virus, fungus, and protozoa), or  
84 infectious substance, or any naturally occurring, bioengineered, or synthesized component of any  
85 such microorganism or infectious substance, capable of causing: death, disease, or other  
86 biological malfunction in a human, an animal, a plant, or another living organism; deterioration  
87 of food, water, equipment, supplies, or material of any kind; or deleterious alteration of the  
88 environment.

89 “Biosafety in Microbiological and Biomedical Laboratories” or “BMBL,” a publication that lists  
90 the standards and special microbiological practices, safety equipment and facilities constituting  
91 Biosafety Levels 1-4, most recent edition, published by the United States Department of Health  
92 and Human Services, Public Health Service, the Centers for Disease Control and Prevention and  
93 the National Institutes of Health. If the publication is discontinued, the most recent edition shall  
94 remain in effect as thereafter modified from time to time by regulation of the department.

95 “Biosafety Level 3 laboratory” or “BSL3 laboratory,” a laboratory that is designed, equipped, or  
96 operated as a biosafety level 3 laboratory as defined by the United States National Institutes of  
97 Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines).

98 “Biosafety Level 4 laboratory” or “BSL4 laboratory,” a laboratory that is designed, equipped, or  
99 operated as a biosafety level 4 laboratory as defined by the United States National Institutes of  
100 Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines).

101 “Department,” the Department of Public Health.

102 “Facility,” a building or combination of buildings under common control and ownership  
103 containing one or more laboratories subject to a common Institutional Biosafety Committee.

104 “High Containment Biological Research Laboratory,” a BSL3 or BSL4 laboratory.

105 “Laboratory,” a room or rooms that are used primarily for biological research, development, non-  
106 routine testing, or experimentation activity, or any room or rooms where vertebrate animals are  
107 contained under animal biosafety levels three and four as described in NIH Guidelines/BMBL  
108 Section IV. The word “laboratory” shall also include those rooms that directly serve a laboratory  
109 and are within the containment area.

110 “National Institutes of Health Guidelines” or “NIH Guidelines,” the National Institutes of Health  
111 Guidelines for Research Involving Recombinant Molecules, as amended from time to time. If  
112 the National Institutes of Health shall discontinue or abolish said guidelines, the most recent  
113 guidelines shall remain in effect as thereafter modified from time to time by regulation by the  
114 department.

115 “Person,” any state, public, or private corporation or authority, any individual, trust, firm, joint  
116 stock company, partnership, association, or other entity, or any group thereof, and any officer,  
117 employee, or agent of such person, any group of persons, and any agency or political subdivision  
118 of the Commonwealth or of the federal government.

119 “Program,” the High Containment Biological Research Laboratory Health and Safety Program.

120 “Select Agents and Toxins,” a biological agent or toxin as defined in Title 42, Part 73 of the  
121 Code of Federal Regulations, Title 9, Part 121 of the Code of Federal Regulations, or Title 7,  
122 Part 331 of the Code of Federal Regulations.

123 “Toxin,” any toxic material or product of plants, animals, microorganisms (including bacteria,  
124 virus, fungus, rickettsiae, or protozoa), or infectious substance, or a recombinant or synthesized  
125 molecule, whatever their origin and method of production, and includes: any poisonous  
126 substance or biological product that may be engineered as a result of biotechnology produced by  
127 a living organism; or any poisonous isomer or biological product, homolog, or derivative of such  
128 a substance.

129 There is established in the department a High Containment Biological Research Laboratory  
130 Health and Safety Program.



131 The program shall provide standards for the location, operation, and maintenance of high  
132 containment biological research laboratories and the oversight of such laboratories to protect the  
133 safety of laboratory workers, the public, and the environment from select agents and toxins.

134 The department shall adopt regulations for the implementation of the program that:

135 Set criteria for determining appropriate locations for siting a building with a BSL4 laboratory,  
136 including whether a BSL4 laboratory may be created within an existing building, that at a  
137 minimum include that:

138 Sites shall not be within a floodplain, near a property whose regular use could significantly  
139 endanger the site through fire or explosion, or near an area of high traffic congestion that might  
140 impede emergency access or evacuation or endanger motorists;

141 Sites shall have sufficient land available to provide for a reasonable buffer around the building, a  
142 minimum of 150 unobstructed feet in every direction;

143 Other criteria for consideration include: the proximity of flood plains, wetlands, waterways, and  
144 water bodies; the relationship of the site to groundwater elevations; the nature and extent of  
145 residential areas and schools through grade twelve in proximity to the site; the availability and  
146 suitability of access roads to the site, including the ability of first responders to access the site in  
147 an emergency; the potential for adverse public health and safety impacts; the potential impact of  
148 increased traffic volume on roads to the site; and the potential threat of a terrorist attack on or  
149 infiltration of the building.

150 Provide a process to determine whether to approve the siting of a new BSL4 laboratory that  
151 includes:

152 An application to be completed by a person wishing to site a building with a BSL4 laboratory or  
153 add a BSL4 laboratory to an existing building that did not have a BSL4 laboratory;

154 The department holding a public hearing on the application in the municipality where the  
155 laboratory would be located;

156 The department, the department of environmental protection, the board of health of the  
157 municipality in which the facility would be located reviewing the application and approving the  
158 siting if they determine that the proposed site and building would not constitute a threat to the  
159 public health or safety or the environment;

160 The decision on the siting is made in writing with findings as to why the decision was made;

161 The approval or denial of siting may be appealed pursuant to provisions of section fourteen of  
162 chapter thirty A;

163 Require each facility with a BSL4 laboratory that has been approved as required by subsection  
164 (2) to submit to the department the construction plans for the facility, construction schedule, the  
165 application submitted to the National Institutes of Health (NIH), if applicable, the as-built plans  
166 when completed, and documentation of third-party commissioning of the facility.

167

168 Assure that high containment biological research laboratories meet or exceed federal guidelines  
169 for health and safety practices, including that:

170 Each facility with a high containment biological research laboratory complies with the most  
171 current versions of the following guidelines: NIH Guidelines; BMBL; and Guidelines on Primary

172 Containment for Biohazards (Centers for Disease Control/NIH); or more protective regulations  
173 that the department might adopt.

174 Each facility with a high containment biological research laboratory shall establish an  
175 Institutional Biosafety Committee (IBC) in accordance with the NIH Guidelines, whether it is  
176 NIH funded or not. At least two members of the IBC shall be residents of the municipality in  
177 which the facility is located and shall be independent of the facility, its contractors, and  
178 consultants. One such member shall be appointed by the department and the other shall be  
179 appointed by the local board of health. A member appointed by the department or local board of  
180 health may be rejected by the facility only for good cause.

181 An IBC shall comply with NIH Guidelines applicable to IBCs for all research in high  
182 containment biological research laboratories, whether recombinant DNA research or not, and  
183 may be further regulated by the department. Each IBC for a facility with high containment  
184 biological research laboratory shall, at a minimum:

185 (A) Provide the department with a complete list of all members of the IBC, including member's  
186 name, title, business mailing address, phone number, fax number, e-mail, and curriculum vitae.  
187 The list and curriculum vitae shall be updated with any changes at least annually.

188 (B) Review and approve all projects in facilities operating a high containment biological research  
189 laboratory prior to the projects commencing. A protocol registration document, as defined by the  
190 NIH guidelines, shall be required for all approved IBC projects with select agents and toxins and  
191 other regulated agents requiring BSL3 or BSL4 containment. The documents shall be sent to the  
192 department and are subject to chapter 66 of the General Laws.

193 (C) Take and keep minutes of IBC meetings that conform to the NIH Guidelines and provide the  
194 minutes to the department. The minutes shall be accessible for members who do not attend the  
195 meetings. The minutes shall include, but not be limited to: IBC members present at the meeting;  
196 a description of any current or pending research; any comments or concerns made at the meeting;  
197 and any voting, administrative matters, accident reporting or compliance issues discussed. The  
198 department may provide the minutes to the local board of health upon request.

199 (D) Inspect the high containment biological research laboratories at least annually and submit the  
200 results of the inspections to the department.

201 (E) Meet at least annually with a representative of the department to review safety procedures,  
202 discuss health issues relating to operation of its facility, and such other issues identified by the  
203 department.

204 (F) Hold at least one public meeting annually to a report on health and safety issues at the facility  
205 and take public comments about the facility.

206 Require prior approval by the department for research that may or is intended to:

207 Enhance the harmful consequences of a biological agent or toxin. Harmful consequences include  
208 the ability to critically alter normal biological functions, or inflict damage on public health  
209 resources, materiel, and public safety. Enhancement includes augmenting properties such as  
210 virulence, infectivity, stability, transmissibility, or the ability of the biological agent or toxin to  
211 be disseminated;

212 Disrupt immunity or the effectiveness of an immunization;

213 Confer to a pathogenic agent or toxin resistance to clinically or agriculturally useful prophylaxes  
214 or therapeutics against that agent or toxin;

215 Facilitate the ability of a biological agent or toxin to evade detection methodologies;

216 Increase the stability, transmissibility, or the ability to disseminate a biological agent or toxin;

217 Alter the host range or tropism of a pathogenic agent or toxin;

218 Enhance the susceptibility of a host population, including by immuno-modulation of the host to  
219 increase pathogenicity; or

220 Generate a novel pathogenic agent or toxin or reconstitute an eradicated or extinct pathogenic  
221 agent. A novel agent is an agent that has not existed previously and is considered unique based  
222 on biological or other properties and traits.

223 Such approval may be granted only upon a showing that the facility has taken special precautions  
224 to minimize or eliminate health and safety risks arising from such research.

225 Require each facility with a high containment biological research laboratory to complete a permit  
226 application and obtain a permit from the department to operate its high containment biological  
227 research laboratories. Said permits shall contain the terms and conditions the department  
228 determines are necessary to protect worker and public health and safety and the environment.

229 Said permits shall not exceed five years in duration but may be renewed or reissued by the  
230 department after receipt of a new completed permit application that meets regulatory  
231 requirements. The department may issue or renew a permit only upon finding that no condition  
232 or circumstance exists in the facility that is prejudicial to worker or public health and safety or  
233 the environment. The department may suspend or revoke a permit upon finding that a condition

234 or circumstance exists in the facility that is prejudicial to worker or public health and safety or  
235 the environment.

236 Require each facility with a high containment biological research laboratory to have a medical  
237 surveillance plan created in consultation with a licensed physician experienced in occupational  
238 health or infection control and familiar with biological laboratory exposures and informed about  
239 select agents and toxins. The purpose of the plan is to establish employee and researcher  
240 occupational health records, document and require inoculation for diseases when a safe vaccine  
241 is available, screen for illness among laboratory workers, require reporting of laboratory  
242 accidents, monitor and track releases and laboratory-acquired infections and spreads, and report  
243 within the facility and to appropriate government entities. The specifics of the medical  
244 surveillance and infection control protocol must meet standards established by the department  
245 and be approved by the department. The medical surveillance plan shall be implemented  
246 through an employee experienced in occupational health or infection control, familiar with  
247 biological laboratory exposures, and informed about select agents and toxins. The employee  
248 shall also:

249 Report any accidental or intentional human exposure to a pathogenic biological agent or toxin, or  
250 reasonable likelihood of such exposure, to the department as soon as possible and in no case  
251 more than 24 hours after learning of the exposure;

252 Report any accidental or intentional release or spread of a pathogenic biological agent or toxin,  
253 or reasonable likelihood of a release or spread, outside the containment area of a BSL 3 or BSL4  
254 laboratory to the department as soon as possible, and in no case more than 24 hours after the

255 release. The report also shall be provided to the board of health in the municipality in which the  
256 facility is located and any other municipality affected by the release.

257 Provide the IBC with a report of all incidents, accidents, and other events that caused or are  
258 suspected to have caused a threat to the public health, death, illness, or bodily injury to any  
259 person in the laboratory, as they occur, but no later than 3 days after the incident.

260 Require each facility with a high containment biological research laboratory to have and  
261 implement a plan to provide adequate training for the proper handling of pathogenic biological  
262 agents and toxins that might be present in the laboratory. Such training shall include, but not be  
263 limited to, decontamination methods, personnel safety precautions and work habits, early  
264 warning disease surveillance, and accident response actions and notifications. The facility shall  
265 provide a training plan to its IBC and the department for approval and shall update the plan  
266 annually, if necessary. The training plan shall ensure that all laboratory staff and researchers,  
267 including the principal investigator for each facility, are trained adequately and that the principal  
268 investigator participates in the creation and implementation of the training plan. No individual  
269 other than a local, state or federal government representative requiring access for regulatory  
270 compliance or investigative purposes may enter a high containment biological research  
271 laboratory located within a facility without first completing the facility's training plan.

272 Require each facility with a high containment biological research laboratory to have and  
273 implement a waste management and decontamination plan approved by the department.

274 A facility with a high containment biological research laboratory shall develop an emergency  
275 response plan, in conjunction with local and state officials, that addresses security threats and  
276 releases and spread of pathogenic biological agents and toxins. The emergency response plan

277 shall comply with local, state or federal plans already in existence. The plan must address such  
278 events as severe weather (such as hurricanes and floods), earthquakes, power outages, terrorism,  
279 and other natural, accidental, or intended disasters or emergencies. The emergency response plan  
280 shall at a minimum address the following:

281 The hazards associated with the use of the select agents and toxins and special procedures  
282 needed to address the hazards of specific select agents and toxins.

283 Personnel roles, lines of authority, training, and communication.

284 Emergency assessment and prevention.

285 Site security and control.

286 Evacuation routes and procedures.

287 Decontamination.

288 Emergency medical treatment and first aid.

289 Emergency alerting and response procedures.

290 Personal protective and emergency equipment.

291 Regularly scheduled preparedness exercises in coordination with local public health and safety  
292 officials.

293 Critique of response and follow-up after an incident has occurred.

294 Communication to the public and news media.



295 A facility with a BSL4 laboratory shall coordinate with a hospital within a five mile radius of the  
296 facility for a medical response to human exposure to a pathogenic biological agent or toxin, and  
297 do so in conformity with existing public health guidelines and regulations. If there is no hospital  
298 medically equipped to coordinate this type of response within a five mile radius of said facility,  
299 then the coordination shall be performed at the closest hospital to the facility so equipped. Said  
300 coordination shall include, but not be limited to, addressing transportation, isolation, and  
301 quarantine issues as appropriate to the diseases caused by select agents and toxins at the facility.

302 If the closest hospital has created a plan in collaboration with the department under the  
303 Bioterrorism Grant Program, the facility is not required to pay for the cost of annual drills.

304 Every facility that has a high containment biological laboratory shall purchase property and  
305 general liability insurance. The insurance shall provide compensation for harm that would be  
306 caused to facility workers and the public in the event of a release of a toxin or agent or other  
307 hazardous exposure to dangerous pathogens, and from damages caused by a terrorist attack on  
308 the facility.

309 No employee, researcher, or student shall be required to conduct scientific research,  
310 experimentation, or study or take other action in a facility with a high containment biological  
311 research laboratory that violates any provision of this section or has reasonable potential to  
312 adversely affect public or worker health, safety, or the environment.

313

314 A facility with a high containment biological research laboratory shall not take any retaliatory  
315 action against an employee, researcher, or student in the facility because that person discloses or  
316 threatens to disclose to a supervisor or a public body an activity, policy or practice that the

317 employee, researcher or student reasonably believes is in violation of this section or objects to or  
318 refuses to participate in any activity, policy or practice that the employee, researcher or student  
319 reasonably believes is in violation of this section.

320 The protection against retaliatory action shall not apply to the public disclosure of confidential or  
321 proprietary information, trade secrets or other confidential materials unless the employee,  
322 researcher or student makes such disclosure directly and exclusively to the office of the attorney  
323 general or the department. The department shall not publicly disclose any such confidential  
324 information, but shall submit the information to the Attorney General forthwith.

325

326 An employee, researcher or student aggrieved by a violation of this subsection may, within two  
327 years, file a complaint with the attorney general, who may bring an action in the name of the  
328 Commonwealth against the facility alleged to have violated this section. Provided further, that  
329 within ninety days of receiving said complaint, the attorney general shall notify the complainant  
330 in writing as to whether he intends to bring an action in the name of the Commonwealth. If the  
331 attorney general declines to bring an action based on the complaint filed, the aggrieved  
332 employee, researcher or student may, within one year, institute a civil action in the superior  
333 court. Any party to said action shall be entitled to claim a jury trial. All remedies available in  
334 common law tort actions shall be available to prevailing plaintiffs. These remedies are in  
335 addition to any legal or equitable relief provided herein. The court may: (i) issue temporary  
336 restraining orders or preliminary or permanent injunctions to restrain continued violation of this  
337 section; (ii) reinstate the employee, researcher or student to the same position held before the  
338 retaliatory action, or to an equivalent position; (iii) reinstate full fringe benefits and seniority

339 rights to the employee, researcher or student; (iv) compensate the employee, researcher or  
340 student for three times the lost wages, benefits and other remuneration, and interest thereon; and  
341 (v) order payment by the facility of reasonable costs, and attorneys' fees.

342 In any action brought by an employee, researcher or student under subsection (2), if the court  
343 finds said action was without basis in law or in fact, the court may award reasonable attorneys'  
344 fees and court costs to the facility. An employee, researcher or student shall not be assessed  
345 attorneys' fees if, after exercising reasonable and diligent efforts after filing a suit, the employee,  
346 researcher or student moves to dismiss the action against the facility, or files a notice agreeing to  
347 a voluntary dismissal, within a reasonable time after determining that the facility would not be  
348 found liable for damages.

349 Nothing in this subsection shall be deemed to diminish the rights, privileges or remedies of any  
350 employee, researcher or student under any other federal or state law or regulation, or under any  
351 collective bargaining agreement or employment contract.

352 A facility with a high containment biological research laboratory shall publicly display notices  
353 designed to inform its employees, researchers and students of their protections and obligations  
354 under this subsection, and use other appropriate means to keep its employees, researchers or  
355 students so informed. Each notice posted pursuant to this subsection shall include the name of  
356 the person or persons the facility has designated to receive written notification of a suspected  
357 violation of this section.

358 A facility with a high containment biological research laboratory shall have a security plan  
359 developed in coordination with state and local public safety officials. The security plan shall  
360 describe the deployment of security guards; the number of guards at each facility; other

361 protective measures, including, coordination of security response with Federal, State, and Local  
362 authorities; restricted personnel access to each BSL3 and BSL4 laboratory; perimeter site  
363 security, internal site security, and fire protection barriers; and background security clearance for  
364 employees and prospective employees. If, at any time, the department of public safety  
365 determines that the security plan or implementation of the security plan for a BSL3 or BSL4  
366 facility or laboratory is insufficient to ensure its security, the municipality or department of  
367 public safety shall submit to the facility a report that identifies the vulnerability of the facility or  
368 laboratory, and recommended actions to eliminate the vulnerability. Said recommendations or  
369 other remedial actions shall be implemented by the facility immediately.

370 To ensure compliance with this section and to protect the public health and safety and the  
371 environment, the department shall have the authority to review all documentation relating to the  
372 operations of a high containment biological research laboratory and conduct physical inspections  
373 of any such laboratory, and any other part of a facility that supports the laboratory, with or  
374 without prior notice; so long as such inspections are conducted at reasonable times and in a  
375 manner that maintains the health and safety systems of the laboratory.

376 A person who willfully or knowingly violates this section or a regulation promulgated pursuant  
377 to this section is subject to judicially imposed criminal and civil penalties as well as civil  
378 administrative penalties. Each day that a violation occurs or continues constitutes a separate  
379 violation. A violation may be punished by the administrative imposition of a penalty of not less  
380 than \$100 and not more than \$25,000 for each day of violation. A violation may be punished by  
381 a fine not less then \$100 and not more than \$25,000, or by imprisonment for not more than two  
382 years in the house of correction. Punishment imposed under this section does not preclude any  
383 other penalty prescribed by law.

384 If a facility or laboratory remains in violation of this section or a regulation promulgated  
385 pursuant to this section after written notice from the department without taking reasonable steps  
386 to alleviate the violation, the department shall have the authority to close the facility or  
387 laboratory until the violation is remedied. If the department finds that an imminent and  
388 substantial threat to worker or public health or safety or the environment exists in a facility or  
389 laboratory, it may request the attorney general bring suit or an action for injunctive relief.

390 Each municipality in the Commonwealth shall have the authority to regulate and prohibit high  
391 containment biological research laboratories within its jurisdiction. If a municipality has a  
392 regulatory program for high containment biological research laboratories that the department  
393 finds is at least as protective of worker and public health and safety and environment as this  
394 program, upon request of the municipality the department may certify the municipal program to  
395 operate in the place of this program in the municipality.

396 SECTION 2. The Department of Public Health shall adopt regulations to implement this act  
397 within one year after the effective date of this act.

398 SECTION 3. Section 19(d)(2), concerning whether to approve the siting of a new BSL4  
399 laboratory, shall not apply to any building intended to include a BSL4 laboratory that has a  
400 building permit and is under construction as of the effective date of this act.